Newsmakers: Peter Stevenson

By Tim Wright, Editor | March 9, 2016

Pfizer’s VP, contract mfg., talks about integrating Hospira One 2 One

When Pfizer bought Hospira last year, the acquisition expanded Pfizer’s portfolio of sterile injectable pharmaceuticals, which include anti-infectives, anti-inflammatories and cytotoxics, with Hospira’s generic sterile injectables product line, including acute care and oncology injectables, with a number of differentiated presentations. A good move on Pfizer’s part, considering the global market value for both generic sterile injectables and biosimilars is expected to grow, estimated to be $70 billion and $20 billion in 2020, respectively.

After the purchase, the contract manufacturing operations of both organizations—Pfizer CentreSource and Hospira One 2 One—began operations as a combined business, but still under separate names. One 2 One’s expertise in parenteral contract development and manufacturing continued alongside CentreSource’s existing API contract manufacturing business.

However, soon these combined businesses that bring together the best of Pfizer and Hospira capabilities, providing a wider array of services and manufacturing technology to clients, will do so under a new, unified CMO banner.

Peter Stevenson, vice president, contract manufacturing and portfolio management, Pfizer, filled Contract Pharma in on plans that are in the works to bring both operations together to create a new name in the CMO business.                                       —TW

Contract Pharma: Now that Pfizer has acquired Hospira, what are the company’s plans for its contract manufacturing organizations, Pfizer CentreSource and Hospira One 2 One?
Peter Stevenson:
We are integrating the two into one Pfizer CMO and will be unveiling our new brand very soon. As a combined organization, we’re bringing together the best of our contract manufacturing capabilities to grow our CMO beyond what it would achieve as standalone businesses. That way, we can provide a wider array of services and technologies to our biopharmaceutical partners while driving continuous improvement.

CP: How is the new CMO structured?
We’ve aligned the CMO into two primary businesses: API and drug product.  The API business will focus on custom API synthesis, steroid/hormone intermediates and APIs, and high-potency APIs. The drug product business will focus on building on our strength in sterile injectables fill-finish, which helped our partners launch 7 new drugs in the last two years alone. 

CP: What is the CMO’s organizational relationship with Pfizer?
We’re a separate, embedded CMO service business within Pfizer that reports through Pfizer’s commercial organization, which structurally underscores our partner-centric focus. We have our own dedicated team and devote our complete attention to our biopharma partners and their molecules. But we also have the backing and resources of Pfizer. This combination enables us to really come through for our partners.

CP: Is Pfizer dedicating plant time and resources to CMO customers?
Yes. Legacy Hospira One 2 One worked this way very successfully, and Pfizer is adopting this model for the new CMO as a best practice. Although Pfizer is best known for its proprietary drugs, we’ve been in the contract manufacturing business since 1973. With the integration of One 2 One, we’re excited to be able to expand and strengthen what our CMO can offer. As the leader of Pfizer’s CMO business, let me be unequivocal:  We are committed to growing our business and servicing our biopharma partners for the long haul.

CP: What stands out about Pfizer’s CMO?
Our people, first and foremost. Our biopharma partners rely on us for guidance, problem solving and follow-through. Our staff invest themselves as true collaborators and will pull out all the stops to get things done, and done right on behalf of our partners.  
On the more tangible side, Pfizer offers an impeccable quality, regulatory and supply-assurance track record, along with robust manufacturing expertise and infrastructure. Pfizer has its own portfolio of biopharmaceuticals and injectables, which keeps our manufacturing sites at the cutting edge of new technologies and requires continual investment in talent and capital. Another standout is our strong program management. If our biopharma partners don’t meet their critical deadlines, we haven’t truly delivered for them. 

Tim Wright is editor of Contract Pharma. He can be reached at twright@rodmanmedia.com.

Related Contract Manufacturing:

Related Packaging: